Habib Hamidi

2.9k total citations
41 papers, 1.2k citations indexed

About

Habib Hamidi is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Habib Hamidi has authored 41 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Molecular Biology, 19 papers in Oncology and 15 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Habib Hamidi's work include Cancer Immunotherapy and Biomarkers (8 papers), Multiple Myeloma Research and Treatments (7 papers) and Renal cell carcinoma treatment (5 papers). Habib Hamidi is often cited by papers focused on Cancer Immunotherapy and Biomarkers (8 papers), Multiple Myeloma Research and Treatments (7 papers) and Renal cell carcinoma treatment (5 papers). Habib Hamidi collaborates with scholars based in United States, Switzerland and France. Habib Hamidi's co-authors include Dennis J. Slamon, Gottfried E. Konecny, Chen Wang, Ellen L. Goode, Charles Ginther, Jason R. Wild, Susan E. Bates, Boris Winterhoff, Jerry J. Jaboin and Robert W. Robey and has published in prestigious journals such as Journal of Biological Chemistry, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Habib Hamidi

36 papers receiving 1.2k citations

Peers

Habib Hamidi

ONCOL

PRM

Karen G. Montgomery Australia

Elisabeth Wik Norway

Russell Broaddus United States

Gabriel Ricolleau France

Lydia Gaba Spain

Andrea E. Wahner Hendrickson United States

Daryl Johnson Australia

Jacqui Rowbottom United Kingdom

Michael Xiang United States

Clare Orange United Kingdom

Karen G. Montgomery Australia

Habib Hamidi

1.1k ×1.7

528 ×1.2

ONCOL

397 ×1.2

PRM

362 ×1.2

143 ×0.6

Citations per year, relative to Habib Hamidi Habib Hamidi (= 1×) peers Karen G. Montgomery

Countries citing papers authored by Habib Hamidi

Since Specialization

Citations

This map shows the geographic impact of Habib Hamidi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Habib Hamidi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Habib Hamidi more than expected).

Fields of papers citing papers by Habib Hamidi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Habib Hamidi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Habib Hamidi. The network helps show where Habib Hamidi may publish in the future.

Co-authorship network of co-authors of Habib Hamidi

This figure shows the co-authorship network connecting the top 25 collaborators of Habib Hamidi. A scholar is included among the top collaborators of Habib Hamidi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Habib Hamidi. Habib Hamidi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rini, Brian I., Laurence Albigès, Xiaobin Tang, et al.. (2025). Circulating kidney injury molecule-1 (KIM-1) and association with outcome to adjuvant immunotherapy in renal cell carcinoma. Annals of Oncology. 36(12). 1525–1534.

Lu, Tianshi, Habib Hamidi, Mark A. Socinski, et al.. (2025). Non-small cell lung cancer molecular subtypes and vulnerability to immunotherapy treatment combinations. Nature Communications. 17(1). 122–122.

Qu, Xueping, Habib Hamidi, Radia Marie Johnson, et al.. (2025). Ligand-activated EGFR/MAPK signaling but not PI3K, are key resistance mechanisms to EGFR-therapy in colorectal cancer. Nature Communications. 16(1). 4332–4332. 3 indexed citations

Murphy, Connor, Heather Fairfield, Victoria DeMambro, et al.. (2025). Inhibition of acyl‐ CoA synthetase long‐chain isozymes decreases multiple myeloma cell proliferation and causes mitochondrial dysfunction. Molecular Oncology. 19(6). 1687–1706. 3 indexed citations

Johnson, Travis S., Parvathi Sudha, Vivek S. Chopra, et al.. (2025). Utilizing genomics to identify novel immunotherapeutic targets in multiple myeloma high-risk subgroups. Genome Medicine. 17(1). 79–79.

Wong, Sandy W., Habib Hamidi, Luciano J. Costa, et al.. (2023). Multi-omic analysis of the tumor microenvironment shows clinical correlations in Ph1 study of atezolizumab +/- SoC in MM. Frontiers in Immunology. 14. 1085893–1085893. 3 indexed citations

Hamidi, Habib, Diana Dunshee, Brian Higgins, Monique Dail, & Michael Boyiadzis. (2023). Clinico-Genomic Characterization of AML Patients Based on IL2RA (CD25) Expression Uncovers an Association with Stem Cell Signatures and FLT3-ITD Status and Informs Drug Combinations. Blood. 142(Supplement 1). 4329–4329.

Verstovšek, Srđan, Lynda Foltz, Vikas Gupta, et al.. (2023). Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trial. Haematologica. 108(10). 2730–2742. 13 indexed citations

Krishnan, Venkatesh, Ching‐Wei Chang, Habib Hamidi, et al.. (2023). Abstract 5702: Ovarian cancer tumor microenvironment and atezolizumab (atezo) clinical activity: IMagyn050 sub-study. Cancer Research. 83(7_Supplement). 5702–5702. 1 indexed citations

10.

Schjesvold, Fredrik, Bruno Paiva, Vincent Ribrag, et al.. (2022). Cobimetinib Alone and Plus Venetoclax With/Without Atezolizumab in Patients With Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 23(1). e59–e70. 10 indexed citations

11.

Rajasekaran, Kamalakannan, et al.. (2022). Tetramer-aided sorting and single-cell RNA sequencing facilitate transcriptional profiling of antigen-specific CD8+ T cells. Translational Oncology. 27. 101559–101559. 1 indexed citations

12.

Wang, Jin, Yi Hu, Habib Hamidi, et al.. (2022). Immune microenvironment characteristics in multiple myeloma progression from transcriptome profiling. Frontiers in Oncology. 12. 948548–948548. 8 indexed citations

13.

Cho, Hearn Jay, Sandy W. Wong, Aparna Raval, et al.. (2021). P-071: Multi-omic analysis of the tumor microenvironment reveals novel associations in a clinical trial of atezolizumab ± daratumumab for relapsed/refractory multiple myeloma. Clinical Lymphoma Myeloma & Leukemia. 21. S78–S78. 1 indexed citations

14.

Hamidi, Habib & Matthias Kretzler. (2018). Systems biology approaches to identify disease mechanisms and facilitate targeted therapy in the management of glomerular disease. Current Opinion in Nephrology & Hypertension. 27(6). 433–439. 4 indexed citations

15.

Way, Gregory P., Chen Wang, Habib Hamidi, et al.. (2016). Comprehensive Cross-Population Analysis of High-Grade Serous Ovarian Cancer Supports No More Than Three Subtypes. G3 Genes Genomes Genetics. 6(12). 4097–4103. 26 indexed citations

16.

Winterhoff, Boris, Habib Hamidi, Chen Wang, et al.. (2016). Molecular classification of high grade endometrioid and clear cell ovarian cancer using TCGA gene expression signatures. Gynecologic Oncology. 141(1). 95–100. 40 indexed citations

17.

Konecny, Gottfried E., Chen Wang, Habib Hamidi, et al.. (2014). Prognostic and Therapeutic Relevance of Molecular Subtypes in High-Grade Serous Ovarian Cancer. JNCI Journal of the National Cancer Institute. 106(10). 267 indexed citations

18.

Drew, Brian G., Habib Hamidi, Zhenqi Zhou, et al.. (2014). Estrogen Receptor (ER)α-regulated Lipocalin 2 Expression in Adipose Tissue Links Obesity with Breast Cancer Progression. Journal of Biological Chemistry. 290(9). 5566–5581. 59 indexed citations

19.

Garon, Edward B., Richard S. Finn, Habib Hamidi, et al.. (2013). The HSP90 Inhibitor NVP-AUY922 Potently Inhibits Non–Small Cell Lung Cancer Growth. Molecular Cancer Therapeutics. 12(6). 890–900. 56 indexed citations

20.

Hamidi, Habib, Marlena S. Fejzo, Stephen P. Letrent, et al.. (2013). Dacomitinib, an Irreversible Pan-ErbB Inhibitor Significantly Abrogates Growth in Head and Neck Cancer Models That Exhibit Low Response to Cetuximab. PLoS ONE. 8(2). e56112–e56112. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact